BioCardia Surges on FDA Minutes Showing CardiAMP Trial Can Support PMA
BioCardia shares surged 52% to $1.40 after FDA meeting minutes confirmed its CardiAMP HF II trial may support a PMA for heart-failure cell therapy, bucking a weak biotech sector.
Regulation
